Status:
COMPLETED
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Translational Breast Cancer Research Consortium
Beth Israel Deaconess Medical Center
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
20+ years
Brief Summary
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or bre...
Detailed Description
Patients will undergo a breast biopsy at which the area found to be ALH or LCIS on core biopsy will be removed surgically through a small incision in the breast. * The surgical biopsy specimen will b...
Eligibility Criteria
Inclusion
- Women 20 years of age or older
- Imaging abnormality necessitating a core needle biopsy
- Core needle biopsy revealing ALH or LCIS
- Patients may have a history of fibroadenoma and/or proliferative breast lesions with atypia
Exclusion
- History and/or concomitant diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS)
- A palpable abnormality diagnosed by core needle biopsy to be ALH or LCIS
- Received tamoxifen in the past
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2012
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00146536
Start Date
November 1 2004
End Date
November 1 2012
Last Update
March 31 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Center
Boston, Massachusetts, United States, 02115
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215